Table 1.

Descriptive statistics of study participants at the beginning of the study (baseline) in the analytic dataset with complete data (k = 42) ^$.

			Vaccinated During Study
Variable Name	Level	Total (n)	No	Yes	p-Value *
	-	42	21	21	--
Biological Sex (n [%])
	Male	13	5 (23.8)	8 (38.1)	0.504
	Female	29	16 (76.2)	13 (61.9)	0.504
Age (mean [SD])		42	41.48 (11.66)	46.33 (11.91)	0.189
Days Since Positive qPCR Test (mean [SD])	-	42	127.62 (88.45)	165.33 (115.90)	0.243
Pre-Vaccine Sample (n [%])
	True	42	21 (100)	21 (100)	--
Duration of COVID-19 Symptoms (n [%])
	≤2 Weeks	26	13 (61.9)	13 (61.9)	1.00
	>2 Weeks	16	8 (38.1)	8 (38.1)	--
SARS-CoV-2 anti-Spike-IgG Log10 AU/mL	-	-	4.00 (0.82)	3.88 (0.50)	0.583
SARS-CoV-2 anti-RBD-IgG Log10 AU/mL	-	-	3.63 (0.81)	3.61 (0.49)	0.891
SARS-CoV-2 anti-Nucleocapsid-IgG Log10 AU/mL	-	-	4.09 (0.82)	4.02 (0.72)	0.755
229E-CoV anti-Spike-IgG Log10 AU/mL	-	-	4.33 (0.42)	4.32 (0.53)	0.971
HKU1-CoV anti-Spike-IgG Log10 AU/mL	-	-	4.14 (0.47)	4.19 (0.52)	0.779
NL63-CoV-2 anti-Spike-IgG Log10 AU/mL	-	-	3.60 (0.46)	3.62 (0.41)	0.891
OC43-CoV-2 anti-Spike-IgG Log10 AU/mL	-	-	4.75 (0.53)	4.68 (0.54)	0.642
Follow Up Time (median [SD])	-	-	85 (25.87)	84 (9.20)	0.435
Number of Follow Up Visits Per-Participant (mean [SD])	-	-	5.95 (1.60)	6.90 (0.3)	0.014

^$ Participants are stratified by vaccine status (primary exposure) throughout the study period, k = 21 participants were vaccinated while under observation. Bivariate associations at baseline were examined by testing for a difference in the distribution of covariates between participants who did or did not receive one dose of a COVID-19 vaccine over the study period. * p-values are reported for parametric tests used for continuous (t-test) and categorical variables (χ² test).